Pharma companies bag 40% of US generics

A steady increase in drug approvals and portfolio rationalisation by MNCs resulted in India’s volume share rising by 5% over the last few months, though value is still impacted due to price erosion.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2OqqacZ
via IFTTT